Skip to main content

Table 1 Change in concentrations of laboratory data (mean ± SD)*

From: Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study

 

Sham

BDL

BDL + vehicle

BDL + fenofibrate

Bilirubin (mg/dl)

0.68 ± 0.17

9.05 ± 2.24a

8.98 ± 2.78a

6.02 ± 1.56a,b,c

ALT (IU/L)

45.7 ± 9.7

115.7 ± 16.5a

117.4 ± 20.2a

82.7 ± 12.0a,b,c

AST (IU/l)

78.1 ± 9.6

142.8 ± 17.8a

147.7 ± 24.0a

99.4 ± 13.6a,b,c

GGT (IU/l)

7.7 ± 2.7

37.8 ± 8.0a

34.4 ± 13.1a

26.4 ± 6.2a,b,c

ALP (IU/L)

95.9 ± 19.4

408.2 ± 42.4a

416.0 ± 62.6a

381.6 ± 36.9a,b

TBA (μmol/ml)

3.2 ± 1.2

34.3 ± 3.8a

35.7 ± 2.9a

26.7 ± 4.1a,b,c

TNF-α (pg/mL)

6.2 ± 2.57

45.7 ± 4.61a

43.8 ± 5.86a

32.7 ± 5.6a,b,c

IL-1β (pg/mL)

7.3 ± 3.9

130.3 ± 16.6a

128.3 ± 23.9a

83.2. ± 11.3a,b,c

Tissue MDA levels (nmol/mg protein)

0.5 ± 0.2

4.9 ± 1.2a

4.8 ± 0.9a

2.1 ± 0.4a,b,c

  1. *Comparisons between groups were done by using Kruskal-Wallis test. Paired comparisons are done by using Mann-Whitney U test.
  2. a P < 0.01 versus sham group (Mann-Whitney U after Kruskal-Wallis test)
  3. b P < 0.01 as compared to BDL groups (Mann-Whitney U after Kruskal-Wallis test)
  4. c P < 0.01 as compared to BDL + vehicle groups (Mann-Whitney U after Kruskal-Wallis test)